Cite
Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed ...
MLA
Liu, Minetta C., et al. “Dose-Escalation of Filgrastim Does Not Improve Efficacy: Clinical Tolerability and Long-Term Follow-up on CALGB Study 9141 Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients Using Dose-Intensified Doxorubicin plus Cyclophosphamide Followed ..” Cancer Treatment Reviews, vol. 34, no. 3, May 2008, pp. 223–30. EBSCOhost, https://doi.org/10.1016/j.ctrv.2007.11.004.
APA
Liu, M. C., Demetri, G. D., Berry, D. A., Norton, L., Broadwater, G., Robert, N. J., Duggan, D., Hayes, D. F., Henderson, I. C., Lyss, A., Hopkins, J., Kaufman, P. A., Marcom, P. K., Younger, J., Lin, N., Tkaczuk, K., Winer, E. P., & Hudis, C. A. (2008). Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed .. Cancer Treatment Reviews, 34(3), 223–230. https://doi.org/10.1016/j.ctrv.2007.11.004
Chicago
Liu, Minetta C., George D. Demetri, Donald A. Berry, Larry Norton, Gloria Broadwater, Nicholas J. Robert, David Duggan, et al. 2008. “Dose-Escalation of Filgrastim Does Not Improve Efficacy: Clinical Tolerability and Long-Term Follow-up on CALGB Study 9141 Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients Using Dose-Intensified Doxorubicin plus Cyclophosphamide Followed ..” Cancer Treatment Reviews 34 (3): 223–30. doi:10.1016/j.ctrv.2007.11.004.